Critical Outcome Technologies Inc. (COTI)

Critical Outcome Technologies Inc. (COTI)

January 25, 2010 17:00 ET

Critical Outcome Technologies Inc. Announces Board Changes

LONDON, ONTARIO--(Marketwire - Jan. 25, 2010) - Critical Outcome Technologies Inc. (COTI) (TSX VENTURE:COT), announced today that Dr. Rainer Engelhardt, a long serving independent member of the Board of Directors (Board), advised the Board at its meeting of January 21, 2010, that he had accepted a new position, as Assistant Deputy Minister, Infectious Disease and Emergency Preparedness Branch of the Public Health Agency of Canada. In accordance with the employment conflict of interest policies of the Government of Canada, Dr. Engelhardt further advised he was resigning from the Board effective January 22, 2010.

"We are very pleased for Dr. Engelhardt as he embarks on this exciting new career," said John Drake, Chairman of the Board. "We will miss his professionalism, wise counsel and guidance and wish to publicly thank him for his contributions in assisting with the growth of COTI during his tenure on the Board. We know that Canada will be well served with Dr. Engelhardt in this important position."

The Board was also advised at the meeting that Mr. Mark Hlady was resigning from the Board for personal reasons. Mr. Hlady, a three term member of the Alberta legislative assembly, joined COTI's Board upon the amalgamation of COTI and Aviator Petroleum Corporation, a capital pool company, which was COTI's going public transaction in October 2006.

"Mr. Hlady was a very important contributor to our success in completing our going public transaction with Aviator," stated Mr. Drake. "His energy, enthusiasm and creative thinking were valuable inputs at our Board meetings these past three years and we wish him much success in his future endeavours."

These resignations bring the current Board to seven members. The Governance and Nominating Committee will be meeting shortly to address any changes to the Board's committees as a result of these resignations as well as to consider the search for new directors.

About Critical Outcome Technologies Inc. (COTI)

COTI is formed around a unique computational platform technology called CHEMSAS®, which allows for the accelerated identification, profiling and optimization of targeted small molecules potentially effective in the treatment of human diseases for which current therapy is either lacking or ineffective. Currently, six targeted libraries of lead compounds are under active development; small cell lung cancer, multiple sclerosis, HIV integrase inhibitors, adult acute leukemia, colorectal cancer and Alzheimer's disease.

For further information, please visit the website at

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Contact Information